Endoplasmic Reticulum Stress Gene Induction and Protection From Ischemia/Reperfusion Injury in the Hearts of Transgenic Mice With a Tamoxifen-Regulated Form of ATF6

Joshua J. Martindale, Rayne Fernandez, Donna Thuerauf, Ross Whittaker, Natalie Gude, Mark A. Sussman and Christopher C. Glembotski

Circ. Res. 2006;98;1186-1193; originally published online Apr 6, 2006;
DOI: 10.1161/01.RES.0000220643.65941.8d

Circulation Research is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2006 American Heart Association. All rights reserved. Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/cgi/content/full/98/9/1186

Subscriptions: Information about subscribing to Circulation Research is online at http://circres.ahajournals.org/subscriptions/

Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, a division of Wolters Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone: 410-528-4050. Fax: 410-528-8550. E-mail: journalpermissions@lww.com

Reprints: Information about reprints can be found online at http://www.lww.com/reprints
Endoplasmic Reticulum Stress Gene Induction and Protection From Ischemia/Reperfusion Injury in the Hearts of Transgenic Mice With a Tamoxifen-Regulated Form of ATF6

Joshua J. Martindale, Rayne Fernandez, Donna Thierauf, Ross Whittaker, Natalie Gude, Mark A. Sussman, Christopher C. Glembotski

Abstract—Ischemia/reperfusion (I/R) affects the integrity of the endoplasmic reticulum (ER), the site of synthesis and folding of numerous proteins. Therefore, I/R may activate the unfolded protein response (UPR), resulting in the induction of a collection of ER stress proteins, many of which are protective and function to resolve the ER stress. In this study, we showed that when mouse hearts were subjected to ex vivo I/R, the levels of 2 ER stress-inducible markers of the UPR, the ER-targeted cytoprotective chaperones glucose-regulated proteins 78 and 94 (GRP78 and GRP94), were increased, consistent with I/R-mediated UPR activation in the heart. The UPR-mediated activation of ATF6 (Activation of Transcription Factor 6) induces cytoprotective ER stress proteins, including GRP78 and GRP94. To examine whether ATF6 protects the myocardium from I/R injury in the heart, we generated transgenic (TG) mice featuring cardiac-restricted expression of a novel tamoxifen-activated form of ATF6, ATF6-MER. When NTG and ATF6-MER TG mice were treated with or without tamoxifen for 5 days, only the hearts from the tamoxifen-treated TG mice exhibited increased levels of many ER stress–inducible mRNAs and proteins; for example, GRP78 and GRP94 transcript levels were increased by 8- and 15-fold, respectively. The tamoxifen-treated TG mouse hearts also exhibited better functional recovery from ex vivo I/R, as well as significantly reduced necrosis and apoptosis. These results suggest that the UPR is activated in the heart during I/R and that, as a result, the ATF6 branch of the UPR may induce expression of proteins that can function to reduce I/R injury. (Circ Res. 2006;98:1186-1193.)

Key Words: unfolded protein response ■ ischemia/reperfusion ■ ATF6

Ischemia and reperfusion (I/R) injury causes a loss of cardiac function via oxidative stress, calcium dysregulation, and eventual myocyte death.1 The endoplasmic reticulum (ER) senses oxidative stress, maintains calcium homeostasis, and can trigger apoptotic signaling.2,3 I/R can affect the ability of the ER to synthesize, fold, and sort proteins and may, therefore, lead to ER stress and activation of the unfolded protein response (UPR). The UPR alleviates ER stress by decreasing protein synthesis and increasing the expression of molecular chaperones that promote proper folding4 and cellular recovery. However, if the ER stress goes unresolved, the UPR can initiate apoptosis.5 Recent reports show that the UPR is activated in cardiac myocytes in response to hypoxia6 and may play a role in the pathogenesis of heart disease.7

An important mediator of ER stress is ATF6 (Activation of Transcription Factor 6), a 670 amino acid ER-transmembrane protein with the N terminus oriented toward the cytosol and the C terminus toward the ER lumen.8 ER stress causes the translocation of ATF6 from the ER to the Golgi,9 where it is cleaved by regulated intramembrane proteolysis (RIP).10 The resulting N-terminal portion of ATF6, approximately 400 amino acids, translocates to the nucleus, where it induces expression of numerous proteins involved with reestablishing ER homeostasis.8 The role of the UPR in I/R damage has been studied to some extent in the brain11–13 and in tumor cells14,15; however, only a few studies have touched on the role of the UPR in the heart. The UPR is active in the myocardium following transaortic constriction,16 suggesting a role for the UPR during myocardial overload. Also, a mutant form of the KDEL receptor, which is involved with ER protein targeting, induced the UPR in the heart and caused dilated cardiomyopathy.7 We recently showed that ATF6 is activated in cardiac myocytes by ER stress,17 Several ATF6-inducible gene products protect cardiac myocytes and/or the heart from various stresses, including I/R.18,19 In the present study, we determined whether activated ATF6 protects the myocardium from I/R injury. We developed a novel ligand-
regulated form of ATF6 by fusing a constitutively active N-terminal fragment of ATF6 to the mutated estradiol receptor (MER). Transgenic (TG) mice that express this ATF6-MER fusion protein in cardiac myocytes were prepared; although the ATF6-MER fusion protein was constitutively expressed in mouse heart myocytes, it was active only in the presence of tamoxifen. The hearts of ATF6-MER TG mice exhibited tamoxifen-dependent protection from I/R-induced injury, as well as the induction of numerous ER stress response genes that encode potentially protective proteins.

Materials and Methods

Primary Neonatal Rat Cardiomyocyte Cultures

Primary cultures of neonatal rat ventricular cardiomyocytes (NRVCMs) were prepared as previously described.20

Luciferase Assays

NRVCMs were cotransfected with plasmids encoding SV40–β-galactosidase (pCH110, Amersham), glucose-regulated protein 78 (GRP78)-ERSE- luc, and ATF6(39-373)-MER. After 24 hours in 10% FBS, cells were treated with vehicle (ethanol) or tamoxifen for 24 hours. Cells were harvested for reporter enzyme assays as previously described.21

Animals

Approximately 300 C57/BL6 mice (Harlan Sprague–Dawley), 8 to 12 weeks old were studied. All procedures involving animals were in accordance with the San Diego State University Institutional Animal Care and Use Committee. Unless otherwise noted, each experiment was performed using a mixture of male and female mice.

Generation of ATF6-MER TG Mice

Constructs encoding various forms of Flag-ATF6 were prepared as described21 and then fused to amino acids 281 to 599 of the murine estrogen receptor (ER) harboring a G-to-R mutation at amino acid 24 hours. Cells were harvested for reporter enzyme assays as previously described.21

Immunoblotting

Tissue extracts (25 to 50 μg of protein) were fractionated on Bio Criterion XT Precast Gels (Bio-Rad) and transferred to polyvinylidene difluoride membranes (Perkin Elmer, Boston, Mass). Primary antibodies used for immunoblotting were anti-Flag (Sigma); anti-KDEL, which cross-reacts with GRP94 and 78K,10,22,23 and anti-ERP72 (Stressgen, Victoria, BC); anti-ATF6 (N terminus), anti-GRP78, anti-CHOP/GADD153, anti-PDI (Santa Cruz Biotechnology, Santa Cruz, Calif); and anti-GAPDH (Research Diagnostics, Concord, Mass). Secondary antibodies were horseradish peroxidase–conjugated (Jackson Immunoresearch, West Grove, Pa). Membranes were incubated with ECL Plus (Amersham, Piscataway, NJ), and chemiluminescence was assessed on a Molecular Dynamics Storm System. Quantification was performed using ImageQuant v5.2.

RNA Analysis

RNA was extracted from hearts using RNAzol (Tel-Test, Friendswood, Tex). cDNA was generated by reverse transcriptase reaction using Superscript III (Invitrogen, Carlsbad, Calif). Real-time quantitative PCR was performed on cDNAs using the Quanti-Tect SYBR Green PCR Kit (Qiagen, Valencia, Calif) and an ABI Prism 7000 (Applied Biosystems, Foster City, Calif). The following primers were used:

1. ANP: 5’-GCTCCAGGGCATATTGGAGG; 3’-GGGGAAGTGAGTCCTACCTTCT
2. Arnt: 5’-AGAAGATCTGGAGACCTGG; 3’-ACTTTT-CTGCACAGGCTTGGC
3. β-Mycosin heavy chain: 5’-AGATGTTTTTTGTGCGATAGA; 3’-CAGTCACCCTGCTTCATCCT
4. Calnexin: 5’-GGGAGTCTTGTGCGATAGA; 3’-TGC-TTTCCAGAGCAGCAG
5. Calreticulin: 5’-ACATAGGGAGCTAAAGAAGC-GCC; 3’-TGAAACATACCTGGCCACCT
6. Chop: 5’-CTTGTGCTTTGGCCACACTG; 3’-GC-CTTGGTA-CACTTGCGAGAG
7. EDEM: 5’-GACCCACCGCTCTACGCAA; 3’-GT-CTTACGA-GCTGCACACTGA
8. Erdj4: 5’-CTTGTCGTTCCTGGCCACACTG; 3’-CAC-AGAG-TGGAAGTGCATGACCC
9. ERO-1L: 5’-AGGGGTCCTTCTCCAAGGTCTG; 3’-AGC-CTGGAAAATCTGAGGGCCCTCA
10. p58IPK: 5’-CAGTCACCGTCTTGCCATTCT; 3’-CTGTTGCAAGAGGAGGAGGAGG
11. GAPDH: 5’-ATGTTCACAGTATGACTCCACTCG; 3’-GAAGAAGCCACTGTAGCTCC
12. GRP78: 5’-ACGTCACCAACCCCGAGGA; 3’-AT-ATCCA-GTGCCGTTCCAGG
13. Herp: 5’-GCGAAGCTGGTGCTTTCAT; 3’-CT-GAAGTC-ACCCATATCT
14. PDI: 5’-TG-TCC-TACGGCCTTGTGGTGAGAAC; 3’-CTCGGATTCCGAGTTCGACG
15. Xbp1: 5’-TG-CTTCAGGCCACGCTT; 3’-GCTGACTTTAAC
16. PDIR: 5’-CTGCTGAGCCAGGT; 3’-ATGACGGTCTTCTG
17. ERp72: 5’-CACTGGCTCTGCCCCAATCAT; 3’-CA-GGCCAACGACAGCAAGT
18. GRP94: 5’-CTCGGATTCCGAGTTCGACG
19. ANP: 5’-GCTCCAGGGCATATTGGAGG; 3’-GGGGAAGTGAGTCCTACCTTCT
20. Arnt: 5’-AGAAGATCTGGAGACCTGG; 3’-ACTTTT-CTGCACAGGCTTGGC
21. β-Mycosin heavy chain: 5’-AGATGTTTTTTGTGCGATAGA; 3’-CAGTCACCCTGCTTCATCCT
22. Calnexin: 5’-GGGAGTCTTGTGCGATAGA; 3’-TGC-TTTCCAGAGCAGCAGC
23. Calreticulin: 5’-ACATAGGGAGCTAAAGAAGC-GCC; 3’-TGAAACATACCTGGCCACCT
24. Chop: 5’-CTTGTGCTTTGGCCACACTG; 3’-GC-CTTGGTA-CACTTGCGAGAG
25. EDEM: 5’-GACCCACCGCTCTACGCAA; 3’-GT-CTTACGA-GCTGCACACTGA
26. Erdj4: 5’-CTTGTCGTTCCTGGCCACACTG; 3’-CAC-AGAG-TGGAAGTGCATGACCC
27. ERO-1L: 5’-AGGGGTCCTTCTCCAAGGTCTG; 3’-AGC-CTGGAAAATCTGAGGGCCCTCA
28. p58IPK: 5’-CAGTCACCGTCTTGCCATTCT; 3’-CTGTTGCAAGAGGAGGAGGAGG
29. GAPDH: 5’-ATGTTCACAGTATGACTCCACTCG; 3’-GAAGAAGCCACTGTAGCTCC
30. GRP78: 5’-ACGTCACCAACCCCGAGGA; 3’-AT-ATCCA-GTGCCGTTCCAGG
31. Herp: 5’-GCGAAGCTGGTGCTTTCAT; 3’-CT-GAAGTC-ACCCATATCT
32. PDI: 5’-TG-TCC-TACGGCCTTGTGGTGAGAAC; 3’-CTCGGATTCCGAGTTCGACG
33. Xbp1: 5’-TG-CTTCAGGCCACGCTT; 3’-GCTGACTTTAAC
34. PDIR: 5’-CTGCTGAGCCAGGT; 3’-ATGACGGTCTTCTG
35. ANP: 5’-GCTCCAGGGCATATTGGAGG; 3’-GGGGAAGTGAGTCCTACCTTCT
36. Arnt: 5’-AGAAGATCTGGAGACCTGG; 3’-ACTTTT-CTGCACAGGCTTGGC
37. β-Mycosin heavy chain: 5’-AGATGTTTTTTGTGCGATAGA; 3’-CAGTCACCCTGCTTCATCCT
38. Calnexin: 5’-GGGAGTCTTGTGCGATAGA; 3’-TGC-TTTCCAGAGCAGCAGC
39. Calreticulin: 5’-ACATAGGGAGCTAAAGAAGC-GCC; 3’-TGAAACATACCTGGCCACCT
40. Chop: 5’-CTTGTGCTTTGGCCACACTG; 3’-GC-CTTGGTA-CACTTGCGAGAG
41. EDEM: 5’-GACCCACCGCTCTACGCAA; 3’-GT-CTTACGA-GCTGCACACTGA
42. Erdj4: 5’-CTTGTCGTTCCTGGCCACACTG; 3’-CAC-AGAG-TGGAAGTGCATGACCC
43. ERO-1L: 5’-AGGGGTCCTTCTCCAAGGTCTG; 3’-AGC-CTGGAAAATCTGAGGGCCCTCA
44. p58IPK: 5’-CAGTCACCGTCTTGCCATTCT; 3’-CTGTTGCAAGAGGAGGAGGAGG
45. GAPDH: 5’-ATGTTCACAGTATGACTCCACTCG; 3’-GAAGAAGCCACTGTAGCTCC
46. GRP78: 5’-ACGTCACCAACCCCGAGGA; 3’-AT-ATCCA-GTGCCGTTCCAGG
47. Herp: 5’-GCGAAGCTGGTGCTTTCAT; 3’-CT-GAAGTC-ACCCATATCT
48. PDI: 5’-TG-TCC-TACGGCCTTGTGGTGAGAAC; 3’-CTCGGATTCCGAGTTCGACG
49. Xbp1: 5’-TG-CTTCAGGCCACGCTT; 3’-GCTGACTTTAAC

Relative abundance of RNA was calculated by the ΔΔCt method.24 Primers were designed using Primer Express v2.0 (Applied Biosystems, Foster City, Calif). All primers were between 90% to 110% efficient, as assessed by standard curve, and all displayed only 1 dissociation peak.
Echocardiography
Mice were anesthetized with isoflurane, and transthoracic 2D guided M-mode echocardiography was performed using an Acuson Sequoia C256 echocardiograph as previously described.25

Global I/R
Hearts from age-matched (8 to 12 weeks of age) non-TG (NTG) and ATF6-MER TG mice treated with or without tamoxifen were exposed to global no-flow ischemia and reperfusion at 37°C at a flow rate of 2 to 4 mL/min and a pressure of 80 mm Hg, as previously described.26

Lactate Dehydrogenase Assays
Perfusates from the hearts subjected to global I/R were collected after 30 minutes of reperfusion. Aliquots (100 μL) of perfusate were added to an equal volume of lactate dehydrogenase (LDH) assay buffer (240 nmol/L NADH, 5 mmol/L pyruvate, 0.06% BSA in 100 mmol/L phosphate buffer [pH 7.5]). LDH units indicate change in absorbance [NADH] normalized to protein.

Triphenyl Tetrazolium Chloride Staining
Hearts exposed to global ischemia and reperfusion were frozen at −80°C. Hearts were partially thawed and sliced into 1-mm sections. Sections were incubated in 1% triphenyl tetrazolium chloride (TTC) in phosphate buffer (Na2HPO4 88 mmol/L, NaH2PO4 1.8 mmol/L) at 37°C for 10 minutes. Sections were placed on glass slides and scanned on a Canon scanner. Images were quantified using a Wacom tablet and pen with ImageJ to outline the infarct and area at risk.

Terminal Deoxynucleotidyltransferase-Mediated dUTP Nick End Labeling
Hearts exposed to I/R were fixed in 10% neutral-buffered formalin and embedded in paraffin, and 5-μm sections were prepared. Cardiac myocytes were stained with anti–sarcomeric actinin (1:200 dilution; Invitrogen) followed by goat anti-mouse fluorescein isothiocyanate (FITC) (1:200 dilution; Invitrogen). Nuclei were stained with Sigma) and embedded in paraffin, and 5-μm sections were prepared. Apoptotic cardiac myocytes were stained with anti–sarcomeric actinin (1:200 dilution; Invitrogen) followed by goat anti-mouse fluorescein isothiocyanate (FITC) (1:200 dilution; Invitrogen). Nuclei were stained with Sigma followed by goat anti-mouse fluorescein isothiocyanate (FITC) (1:200 dilution; Invitrogen).

Statistics
Data are reported as mean±SEM and analyzed via 1-way ANOVA with Newman–Keuls correction using SPSS version 11.0.

Results
Because I/R affects the integrity of the ER, we determined whether the UPR is activated in the myocardium in response to I/R. Accordingly, isolated perfused mouse hearts were treated with or without I/R, and tissue extracts were analyzed for the levels of glucose-regulated proteins 78 and 94 (GRP78, GRP94), which are well-characterized indicators of UPR activation.27 Compared with control, extracts from hearts subjected to I/R for this brief time exhibited increased GRP94 and 78 (Figure 1A). Although it is unclear whether this induction is beneficial in this setting, these results are consistent with the possibility that ATF6 is activated by I/R.

Because UPR-mediated activation of the transcription factor ATF6 induces numerous cytoprotective proteins, we determined the effects of expressing activated ATF6 in TG mouse hearts. To obviate any effects of the transgene on postnatal cardiac development, we developed a version of ATF6 that could be activated by the estrogen analogue tamoxifen, as has been done for Cre recombinase and c-myc.28,29 The MER was fused to either the N terminus or the C terminus or to both ends of constitutively active forms of ATF6, ie, those that do not possess an ER transmembrane domain but retain a transactivation and DNA-binding domain. When tested in cultured cells, the construct exhibiting the lowest basal activity and the greatest tamoxifen-inducible activity was Flag-ATF6-MER.

Figure 1. Ex vivo I/R of NTG mouse hearts, tamoxifen-regulated activation of Flag-ATF6-MER and generation of Flag-ATF6-MER TG mice. A, Hearts from C57/B6 mice were equilibrated for 175 minutes and then extracted (control) or equilibrated for 30 minutes, followed by 25 minutes of global no-flow ischemia and then 2 hours of reperfusion (I/R) and then extracted. Extracts were fractionated by SDS-PAGE and immunoblotted with anti-GAPDH antibody or with anti-KDEL antibody, which detects the C terminus or to both ends of constitutively active forms of ATF6, ie, those that do not possess an ER transmembrane domain but retain a transactivation and DNA-binding domain. When tested in cultured cells, the construct exhibiting the lowest basal activity and the greatest tamoxifen-inducible activity was Flag-ATF6-MER.

A. NRVMC transfection

B. NRVMC transfection

C. Transgenic mouse construct

D. Tissue extract immunoblot: Flag

ATF6(39-373)-MER

NTG

ATF6(39-373)-MER TG
activity encodes ATF6(39-373) with MER fused to the C terminus, ie, ATF6(39-373)-MER (data not shown). Cotransfection of ATF6(39-373)-MER and GRP78-ERSE-luciferase, a well-characterized ATF6-inducible reporter, showed that in the absence of tamoxifen, ATF6(39-373)-MER exhibited no apparent reporter activity relative to vector alone. In contrast, in the presence of 5 or 10 μmol/L tamoxifen, ATF6(39-373)-MER exhibited approximately 1.5-fold (P<0.05) or 2.5-fold (P<0.001) increases in reporter activity, respectively (Figure 1B). ATF6(39-373)-MER was not responsive to supraphysiological levels of estradiol (0.2 μmol/L). This finding is consistent with previous studies showing that the MER cannot bind estrogen.\(^29\)\(^-\)\(^31\) In vehicle treated cultures, ATF6(39-373)-MER was found to reside primarily in the cytosol, whereas tamoxifen treatment increased localization to the nucleus (not shown).

The Flag-ATF6(39-373)-MER cDNA was cloned into the α-musin heavy chain (α-MHC) promoter construct to create α-MHC-Flag-ATF6-Mer (Figure 1C), which was used to generate ATF6-MER TG mice. Flag immunoblotting demonstrated the cardiac specificity of transgene expression (Figure 1D). Several lines of ATF6-MER TG mice that exhibited somewhat different levels of transgene expression were generated (Figure 2A; Flag, lanes 1 to 6). In general, transgene expression was similar to the levels of endogenous ATF6 expression (Figure 2A; ATF6, **, transgene; *, endogenous; lanes 1 to 6). Whereas the levels of endogenous ATF6 did not change on treatment with tamoxifen (Figure 2A; ATF6, *, lanes 1 to 6 [vehicle] versus 9 to 16 [tamoxifen]), ATF6-MER levels were lower after tamoxifen treatment (Figure 2A; ATF6, **, lanes 1 to 6 [vehicle] versus 9 to 16 [tamoxifen]). This finding is consistent with our previous studies showing that ATF6 becomes more labile when activated\(^21\) and provides further evidence that tamoxifen facilitates the activation of ATF6-MER but not endogenous ATF6, as desired. To assess the ability of ATF6-MER to confer gene induction in vivo, we examined the levels of several known ATF6-inducible proteins. The levels of GRP78 and GRP94 were highest in hearts from tamoxifen-treated ATF-MER TG mice (Figure 2B; GRP78 and KDEL; lanes 1 to 6 [vehicle] versus 9 to 16 [tamoxifen]), which was also observed for 2 other ATF6-inducible proteins, protein disulfide isomerase (PDI) and ERp72 (Figure 2C; PDI and ERp72). However, the proapoptotic protein CHOP which is also regulated by the UPR,\(^32\) was not induced (Figure 2D; CHOP IB), suggesting ATF6 alone does not regulate CHOP protein expression. Mouse line 5644, which exhibited the highest level of ATF6-MER expression, was selected for further study.

The relative abundance of mRNAs encoding several UPR proteins was analyzed by real-time quantitative RT-PCR. The levels of GRP78 and GRP94 mRNA were increased by 8-fold (P<0.05) and 15-fold (P<0.01), respectively, but only in hearts from tamoxifen-treated ATF-MER TG mice (Figure 3A). Members of the PDI family showed similar results, where only the hearts from tamoxifen-treated ATF6-MER mice exhibited a 20-fold increase in PDI (P<0.001), with increases in the PDI homologs P5 and ERp72 of 5-fold (P<0.01) and 35-fold (P<0.001), respectively (Figure 3B). Herp, a protein involved with ER-associated degradation (ERAD) of misfolded proteins, showed a 15-fold tamoxifen-dependent increase in only the ATF6-MER TG mouse hearts (P<0.002) (Figure 3C). The mRNA levels of EDEM, which is also involved in ERAD, showed an apparent increase in hearts from tamoxifen-treated ATF-MER TG mice, but this change did not reach significance (Figure 3C). The mRNA levels of other genes involved with the UPR (namely XBP1, p58\(^\text{ipk}\), and CHOP) showed apparent increases in tamoxifen-treated ATF-MER TG mouse hearts, but none of these changes reached statistical significance (Figure 3D).

**Figure 2.** Immunoblotting of ER stress-related proteins in NTG and ATF6-MER TG mouse hearts. NTG mice and mice from several lines of ATF6-MER TG mice were treated with or without tamoxifen (20 mg/kg) by IP injection daily for 5 days. Aliquots of 25 to 50 μg of cardiac extract protein were assessed by immunoblotting. A, Cardiac extracts from NTG mice and ATF6-MER TG mice from lines 5644, 4412, and 5211 (M, male; F, female) treated with or without tamoxifen were immunoblotted for the transgene (Flag) or endogenous ATF6. Endogenous ATF6 is indicated by *, and the TG ATF6-MER fusion protein is indicated by **. B, Cardiac extracts from animals, as described in Figure 2A, were immunoblotted with a GRP78-specific antibody or with a KDEL-antibody, which detects both GRP78 and GRP94. C and D, cardiac extracts were immunoblotted for the protein disulfide isomerasers PDI and ERp72 (C) or for the proapoptotic protein CHOP (D). GAPDH was used as the loading control for all immunoblots.
inducible, increased on tamoxifen treatment, but this change did not reach statistical significance (Figure 3E). A marker of cardiac hypertrophy, atrial natriuretic peptide, showed an approximate 5-fold increase, in only tamoxifen-treated TG mouse hearts, but it did not reach significance, and β-MHC showed an approximate 8-fold increase, which did reach significance (Figure 3F and 3G). The impact of this finding is unclear, because the tamoxifen-treated ATF6-MER mouse hearts showed no morphological or functional signs of hypertrophy (see below). Interestingly, mRNA levels for a gene of unknown function, Armet, which was previously shown to be induced during the UPR,33 was increased >30-fold in only the hearts from tamoxifen-treated ATF6-MER TG mice (Figure 3H). Messenger RNA levels for the ER calcium-binding proteins, calnexin and calreticulin, the GRP78 ATPase, ERP4, and the PDI oxidase, ERO-II, were also assayed but showed no increase in ATF6-MER TG mice (data not shown).

Histology and echocardiography were performed to examine the effects of ATF6 on cardiac morphology and function. The histology indicated that the TG mice treated with or without tamoxifen exhibited no different cardiac morphological features than NTG mice (not shown). Echocardiography also showed that cardiac chamber sizes and wall thickness of all groups were essentially identical (Table), indicating that none of the treatments affected cardiac dimensions or function.

Because potentially protective proteins were upregulated in the hearts of tamoxifen-treated ATF6-MER mice, we determined whether the hearts would exhibit protection from the effects of ex vivo I/R. The hearts from female or male NTG mice treated with or without tamoxifen and ATF6-MER TG mice treated without tamoxifen showed a maximum left ventricle developed pressure (LVDP) recovery of approximately 20% to 40%, relative to equilibration at 30 minutes of reperfusion (Figure 4). In contrast, hearts from tamoxifen-treated male or female ATF6-MER TG mice exhibited an approximate 70% recovery of LVDP at 30 minutes of reperfusion, which remained statistically significant through 2 hours of reperfusion.

The release of LDH from isolated perfused mouse hearts was examined to assess necrosis. Only the perfusates from tamoxifen-treated ATF6-MER TG mouse hearts showed a significant decrease in LDH following I/R (P<0.05) (Figure 5A), indicating reduced necrosis. Hearts exposed to I/R were stained with TTC. Representative TTC stains display large areas of dead tissue (yellow) in hearts from NTG mice treated with or without tamoxifen and untreated ATF6-MER mice. Conversely, hearts from tamoxifen-treated ATF6-MER TG mice retained substantial viable tissue (red) (Figure 5B),

<table>
<thead>
<tr>
<th>Echocardiographic Analysis of the Left Ventricle</th>
<th>NTG</th>
<th>ATF6-MER TG</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>n</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Heart rate, bpm</td>
<td>549±4</td>
<td>531±24</td>
</tr>
<tr>
<td></td>
<td>491±34</td>
<td>508±3</td>
</tr>
<tr>
<td>Anterior wall thickness, mm</td>
<td>0.76±0.02</td>
<td>0.82±0.05</td>
</tr>
<tr>
<td></td>
<td>0.79±0.04</td>
<td>0.75±0.04</td>
</tr>
<tr>
<td>Posterior wall thickness, mm</td>
<td>0.76±0.02</td>
<td>0.75±0.03</td>
</tr>
<tr>
<td></td>
<td>0.72±0.08</td>
<td>0.76±0.01</td>
</tr>
<tr>
<td>End-diastolic dimension, mm</td>
<td>3.15±0.13</td>
<td>3.48±0.21</td>
</tr>
<tr>
<td></td>
<td>3.58±0.41</td>
<td>3.54±0.12</td>
</tr>
<tr>
<td>End-systolic dimension, mm</td>
<td>2.01±0.05</td>
<td>2.24±0.16</td>
</tr>
<tr>
<td></td>
<td>2.33±0.52</td>
<td>2.44±0.08</td>
</tr>
<tr>
<td>Fractional shortening, %</td>
<td>35.8±3.9</td>
<td>35.5±2.1</td>
</tr>
<tr>
<td></td>
<td>35.9±6.9</td>
<td>31±1.8</td>
</tr>
</tbody>
</table>

Results are shown as mean±SEM.
supporting the hypothesis that activated ATF6 protected the myocardium from I/R injury (Figure 5C).

To assess apoptosis, NTG and TG mice were treated with or without tamoxifen, hearts were isolated and subjected to ex vivo I/R and sectioned, and TUNEL staining was performed. Sections were labeled for sarcomeric actinin to identify cardiac myocytes (Figure 6A), with TOPRO-3 to label nuclei (Figure 6B), and with TUNEL reactions to identify apoptotic cells (Figure 6C). Only TUNEL-positive cells that were clearly surrounded by sarcomeric actinin were scored as apoptotic cardiac myocytes (Figure 6D, arrow). Hearts from NTG mice treated with or without tamoxifen, as well as untreated ATF6-MER TG mice exposed to I/R, exhibited approximately 8% to 10% TUNEL-positive cardiac myocytes in the left ventricle; however, the hearts from tamoxifen-treated ATF6-MER TG mice exhibited only 3% TUNEL-positive cardiac myocytes (P<0.05) (Figure 6E). Taken together with results in Figure 5, these findings are consistent with the hypothesis that activated ATF6 decreased I/R-mediated myocardial tissue damage, necrosis, and apoptosis.

Discussion
The data presented here support the hypothesis that the UPR is induced by I/R in the myocardium, and that the ATF6 branch of the UPR may contribute to protecting the myocardium from I/R damage. Acute activation of ATF6 increased the expression of several ATF6-inducible proteins. This pre-induction of potentially protective proteins may have been responsible for reduced myocardial I/R damage, decreased necrosis and apoptosis, and it may have fostered better functional recovery from I/R, as shown by increased LVDP. To our knowledge, this is the first study to report the protective effects of ATF6 in any tissue, in vivo, and the first demonstration of ATF6-mediated protection of the myocardium from I/R injury.
be determined, it is probable that this protection is achieved via the known effects of these proteins in other tissue and cell types. The ER chaperone activities of GRP78, GRP94, and perhaps ERp72 and PDI may be important for protection; however, GRP78, GRP94, Herp, and ERp72 are also ER calcium-binding proteins, which help to maintain calcium homeostasis in the ER. PDI does not appear to bind calcium directly, but calcium affects its interaction with calreticulin, which in turn regulates the chaperone activity of PDI. Thus, protection of the myocardium from I/R damage by ER stress–response proteins may be the combinatorial result of several mechanisms.

Like many other stress-signaling pathways, the UPR can exert both protective and damaging affects. It is believed that most of the initial UPR responses are oriented toward protection and resolution of the ER stress. However, if the ER stress continues unresolved, the UPR pathways that are activated can enhance apoptosis, which may serve a surveillance role in removing cells that are irreversibly damaged by prolonged ER stress. In the ATF6-MER TG mouse model described in this study, the tamoxifen-mediated ATF6 activation and protection from ER stress may be mimicking the initial, protective role of the endogenous ER stress response. It is possible, however, that prolonged activation of the ATF6 branch of the UPR might have detrimental affects in the heart. Such UPR-mediated apoptosis occurs via several mechanisms, 1 of which involves ATF6-mediated induction of the proapoptotic transcription factor CHOP/GADD153. Although we observed a small increase in CHOP mRNA in tamoxifen-treated ATF6-MER TG mouse hearts, CHOP protein levels did not appear to be induced. Perhaps posttranscriptional mechanisms are also required to induce expression of CHOP protein.

The findings of this study have potential widespread implications beyond the myocardium, because the UPR is conserved among all eukaryotic cells and because the UPR has been suggested to participate in the progression of Alzheimer’s disease, diabetes, and tumorigenesis. Future studies relating the time of ATF6 activation to the extent of myocardial protection, as well as studies examining the roles of other branches of the UPR during I/R damage, will further illuminate the potential involvement of ER stress in cardiac health and pathology.

Acknowledgments

This work was supported by NIH grants HL-63975, NS/HL-25037, and HL-75573 (to C.C.G). J.J.M was a Predoctoral Fellow of the American Heart Association. N.G. and R.W. were fellows of the Rees-Stealy Research foundation and the San Diego State University Heart Institute.

References


